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Abstract
Duchenne muscular dystrophy (DMD) is a severe progressive muscular disorder caused by reading frame disrupting
mutations in the DMD gene, preventing the synthesis of functional dystrophin. As dystrophin provides muscle fiber stability
during contractions, dystrophin negative fibers are prone to exercise-induced damage. Upon exhaustion of the regenerative
capacity, fibers will be replaced by fibrotic and fat tissue resulting in a progressive loss of function eventually leading to
death in the early thirties. With several promising approaches for the treatment of DMD aiming at dystrophin restoration in
clinical trials, there is an increasing need to determine more precisely which dystrophin levels are sufficient to restore
muscle fiber integrity, protect against muscle damage and improve muscle function. To address this we generated a new
mouse model (mdx-Xist
Dhs) with varying, low dystrophin levels (3–47%, mean 22.7%, stdev 12.1, n=24) due to skewed X-
inactivation. Longitudinal sections revealed that within individual fibers, some nuclei did and some did not express
dystrophin, resulting in a random, mosaic pattern of dystrophin expression within fibers. Mdx-Xist
Dhs, mdx and wild type
females underwent a 12 week functional test regime consisting of different tests to assess muscle function at base line, or
after chronic treadmill running exercise. Overall, mdx-Xist
Dhs mice with 3–14% dystrophin outperformed mdx mice in the
functional tests. Improved histopathology was observed in mice with 15–29% dystrophin and these levels also resulted in
normalized expression of pro-inflammatory biomarker genes, while for other parameters .30% of dystrophin was needed.
Chronic exercise clearly worsened pathology, which needed dystrophin levels .20% for protection. Based on these
findings, we conclude that while even dystrophin levels below 15% can improve pathology and performance, levels of
.20% are needed to fully protect muscle fibers from exercise-induced damage.
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Introduction
Duchenne Muscular Dystrophy (DMD) is an X-linked recessive
disorder affecting 1:3500 new born boys. It is characterized by
muscle fiber wasting, functional impairment and eventual death
due to respiratory and heart failure. The underlying causes are
frame-shifting and nonsense mutations in the DMD gene, resulting
in the absence of functional dystrophin protein. Intact dystrophin
anchors the intracellular cytoskeleton to the extracellular matrix
and thereby prevents membrane damage during muscle contrac-
tion [1,2]. An allelic, less severe form of the disease, Becker
muscular dystrophy (BMD) is caused by mutations that maintain
the open reading frame and allow synthesis of internally deleted,
partially functional dystrophin proteins [3,4].
There is no cure for DMD, but many potential therapeutic
compounds currently tested in clinical trials aim at restoration of (a
BMD like) dystrophin [5–12]. These trials at best resulted in the
synthesis of low levels of dystrophin protein. However, it is not yet
known how these levels will affect disease pathology, and which
levels are needed to maintain muscle fiber integrity, to prevent
against exercise-induced damage, or to improve muscle function.
In addition, it is as yet unknown whether low dystrophin levels will
stabilize and/or delay disease progression [8]. In perspective of
further optimization of currently tested potential therapeutic
compounds, detailed studies in this direction are necessary.
Early studies primarily involved female DMD carriers, hetero-
zygous mdx mice and isolated BMD patients expressing less than
50% dystrophin. Female DMD mutation carriers express dystro-
phin in approximately 50% of the fibers (when seen in a transverse
cross section) due to random X-inactivation early in life [13,14].
During life, the proportion of dystrophin positive fibers increases
due to positive selection. It appears that this is sufficient to
maintain skeletal muscle function and fiber integrity in both
human and mice. Although skeletal muscles appear to escape
damage, human carriers are at risk for DMD-associated dilated
cardiomyopathy [15], while no heart failure is observed in
heterozygous mdx mice [16,17]. Nevertheless, symptomatic
carriers have been described, often expressing less than 50% of
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rearrangements [18], or unfortunate skewed X-inactivation in
which the degree of skewedness correlated with disease severity
[13,19–21]. In addition, BMD patients generally have lower levels
of dystrophin and these levels seem to correlate with disease
severity, where levels ,10% are observed in very severe patients
and levels .20% in moderate/mild patients [4,22]. Based on a
case study involving one patient, it appears that dystrophin levels
as low as 30% can be sufficient to largely prevent a muscle
phenotype [23]. The amount of revertant fibers has also been
reported to correlate positively with disease severity [24].
However, reports on BMD and skewed X-inactivation cases
involve low numbers of patients and detailed analysis (e.g.
assessment of dystrophin levels in various muscles) is not possible
for obvious reasons. Thus, there is an increasing need for a mouse
model expressing low levels of dystrophin to allow the detailed
study of the effects of low dystrophin levels on disease pathology.
So far, several attempts have been made to achieve this.
Unfortunately, each had limitations. First, transgenic mice
expressing low levels of full-length or truncated dystrophin of
murine or human origin have been generated to test whether this
results in a less severe phenotype [25,26]. However, from the 13
mouse lines generated, only two expressed dystrophin levels lower
than 50% of wild type in both the quadriceps and diaphragm. The
other lines had higher dystrophin levels or a combination of both
higher and lower levels than wild type. From the two potential
lines, one expressed low dystrophin levels (15% quadriceps and
,5% diaphragm), while the other line expressed higher
dystrophin levels (40% quadriceps and 20% diaphragm), thus
allowing detailed analysis of only two different dystrophin levels.
Dunant et al. generated mdx mice in which dystrophin expression
was driven by a 1.35-kb MCK promoter resulting in abundant
expression in fast-twitch muscles (,50%) and very low expression
in slow-twitch fibers. The heart did not express dystrophin at all
[27]. The fiber type specific dystrophin expression makes this
model less suitable for detailed analysis. In another study, Stillwell
et al. generated chimeric mice expressing various dystrophin levels
depending on the amount of wild type cells incorporated in mdx
blastocytes. Mice expressed dystrophin in skeletal muscles in a very
high (60–100%) or low (,5%) manner [28]. This, combined with
the fact that this method is extremely labour intensive, makes this
approach less favourable for extended studies. The final model
known to express low dystrophin levels is the mdx
3cv mouse. Studies
in the mdx
3cv mouse revealed that even ,5% of dystrophin
increased specific tetanic force and partly prevented against
eccentric contractions induced damage in young but not in old
mice. However, it was insufficient to prevent histopathology, since
severity did not differ from dystrophin negative mdx
4cv mice [29].
Although mdx
3cv mice are easy to generate, dystrophin levels do not
exceed 5%, making studies on the effect of higher dystrophin levels
e.g. 20–30% impossible.
Taken together, these models give an indication that ,50%
dystrophin is sufficient for improvement of many pathological
aspects, however, they are not ideal to assess the effects of low
dystrophin levels on disease pathology in detail. Our study
describes a mouse model expressing low dystrophin levels, based
on non-random X-inactivation. In mammals, X-inactivation is
regulated by the X-inactivation center in which Xist is the key
player [30,31]. Mutations in the Xist promoter can skew the
randomness of X-inactivation resulting in preferential inactivation
(60–90%) of the X-chromosome containing the mutated Xist gene
[32]. Here, non-dystrophic female Xist
Dhs mice with a mutation in
the Xist promoter were crossed with dystrophic mdx males. This
resulted in female mdx-Xist
Dhs mice in which the X-chromosome
containing the wild type dystrophin is preferentially inactivated,
leading to a wide range of low dystrophin levels in individual mice
(Figure 1). Within individual muscle fibers of these pups, a mosaic
pattern of dystrophin expression was observed, in which nuclei
either did or did not express dystrophin. Experiments revealed that
low dystrophin levels have a beneficial effect on muscle integrity,
histology, function and serum biomarkers in a dose dependent
manner.
Results
Mdx-Xist
Dhs mice express varying levels of dystrophin
To study whether low dystrophin levels reduce the dystrophic
pathology of mdx mice, mdx-Xist
Dhs mice carrying a wide range of
low dystrophin levels based on non-random X-inactivation were
bred (Figure 1A). For each mdx-Xist
Dhs mouse, dystrophin levels in
the quadriceps muscle were quantified by Western blot (Figure 1B).
These varied between 3–47% of wild type levels (mean 22.7, stdev
12.1, n=24) (Figure 1C), which correlated well (R=0.97) with the
percentages of dystrophin positive fibers in cross sections of the
same muscle, as assessed by blinded manual counting (Figure 1D).
Dystrophin levels of individual muscles differed (assessed in n=6
mdx-Xist
Dhs mice), with the tibialis anterior and biceps expressing
slightly higher levels than the quadriceps, gastrocnemius and
triceps. Lowest dystrophin levels were found in the diaphragm and
heart (Figure S1A–B). The dystrophin level of the quadriceps was
used to group the mice. Longitudinal sections of the quadriceps
revealed that dystrophin expression along a single whole fiber was
patchy, with nuclei either expressing dystrophin or not (Figure 1E).
This indicates that dystrophin proteins cannot freely diffuse along
the muscle fiber and that nuclei where the normal DMD gene is
not inactivated serve only certain regional domains in the muscle
fiber. Transverse cross sections of several skeletal muscles and
heart revealed that dystrophin positive fibers were most often
grouped together and that these small groups were spread over the
muscle (Figure S1C).
Dystrophin is part of a larger complex of dystrophin-
glycoprotein associated proteins, such as b-dystroglycan and
nNOS. As expected, dystrophin positive fibers of the mdx-Xist
Dhs
mice were also positive for b-dystroglycan and nNOS (Figure
S2A). In absence of dystrophin, the homolog utrophin can partly
take over its function. Muscles of adult mdx mice have significantly
higher utrophin levels than those of adult C57BL/10ScSnJ, as
utrophin is overexpressed in the absence of dystrophin [33]. We
assessed how dystrophin expression influences utrophin expression
for six mdx-Xist
Dhs mice expressing various levels of dystrophin. In
mdx-Xist
Dhs mice with very low dystrophin levels (,15%), utrophin
levels were increased as confirmed by Western blot (Figure S2B,
lane 2 and 6). In contrast, mdx-Xist
Dhs mice with intermediate
dystrophin levels (.15%) had low utrophin levels (lanes 1, 3–5).
We did not observe a decrease in utrophin intensity in dystrophin
positive fibers analyzed by immunohistology (data not shown).
Dystrophin level dependent improvement in muscle
function
To determine the effect of low dystrophin levels on functional
performance, Xist
Dhs, mdx and mdx-Xist
Dhs mice were subjected to a
functional test regime consisting of four functional tests per week
for 12 weeks, during which also body weight and creatine kinase
(CK) levels were monitored. After sacrificing, quadriceps muscles
were isolated and dystrophin levels were determined by Western
blot. K-means clustering was used to divide mdx-Xist
Dhs mice into
three groups in an unbiased way. This resulted in the following
division: ,15%, 15–30% and .30% dystrophin. Mdx mice were
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regime than the other mouse strains (mean weight 26, 24.5 and
18.2 gram for mdx, mdx-Xist
Dhs and Xist
Dhs, respectively). An
increased weight compared to wild type has been described before
for mdx mice [34]. Xist
Dhs mice had a stable body weight from week
11 onwards, while the other models showed a mild increase over
Figure 1. Mdx-Xist
Dhs mice. A. To breed mice with low dystrophin levels, female Xist
Dhs mice, carrying a mutation in the Xist promoter which
coordinates X-inactivation, were crossed with dystrophin negative mdx males. During embryogenesis, the maternal X-chromosome encoding a
functional dystrophin gene will be preferentially (60–90%) inactivated as a result of the mutated Xist promoter. The Xist
Dhs mice were a kind gift from
N. Brockdorff (MRC Clinical Sciences Center, London, UK, current affiliation Department of Biochemistry, University of Oxford, UK). B. Picture of a
representative Western blot. The percentage of dystrophin was determined for the quadriceps of all mdx-Xist
Dhs mice by Western blot (2–9 technical
replicates per mouse). The percentage of individual mice was determined using a concentration curve made from wild type samples. Myosin was
used as a loading control. C. Skewed X-inactivation resulted in dystrophin levels of 3–47% (mean 22.7, stdev 12.1, n=24) (as determined by Western
blot) in the female mdx-Xist
Dhs offspring. Each bar represents the dystrophin level of an individual mouse. The dystrophin levels of the individual mice
belonging to the three dystrophin groups can be appreciated from this graph. D. Dystrophin levels determined by Western blot and manual counting
of dystrophin positive fibers demonstrate a strong correlation (R=0.97). E. Longitudinal sections of a quadriceps stained with dystrophin (green) and
spectrin (red). From the pictures it can be appreciated that dystrophin expression is not homogeneously expressed across the fiber but rather
confined to certain nuclear domains.
doi:10.1371/journal.pone.0031937.g001
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Dhs mice from the three
dystrophin level groups were very similar and fell in between mdx
and Xist
Dhs mice, but significantly (P,0.001) differed from both
(Figure 2A).
CK levels are a measure for muscle condition and are ,500 U/
L in healthy mice. CK levels of the Xist
Dhs mice never exceeded
this threshold and were, averaging 270 U/L, significantly
(P,0.001) lower than levels of the other mouse strains. Mdx mice
had the highest CK levels (average 2700 U/L). When analyzed
over the complete time course, these were significantly (P,0.001,
linear regression) higher than those of mdx-Xist
Dhs mice with
.30% dystrophin (average 1570 U/L). CK levels of mice with
15–30% dystrophin generally fell between those with ,15% and
.30%, showing a clear correlation between CK and dystrophin
Figure 2. Body weight, CK levels and functional performance of the mouse models. A. Normalization towards wild type levels was
observed for bodyweight of the mdx-Xist
Dhs mice. At the end of the functional test regime mdx mice were significantly heavier (P,0.001) than the
other mice. B. CK levels of mdx and mdx-Xist
Dhs mice with low dystrophin levels were both significantly (P,0.001) higher compared to the levels of
mdx-Xist
Dhs mice with .30% dystrophin and Xist
Dhs mice. C. Four limb hanging wire performance was comparable for the Xist
Dhs and mdx-Xist
Dhs
mice, while mdx mice performed significantly (P,0.001) worse. D. The best performance on the two limb hanging wire test was obtained for the
Xist
Dhs, mdx-Xist
Dhs with ,15% and 15–30% while the mdx and mdx-Xist
Dhs with .30% dystrophin performed significantly (P,0.001) worse. Bad
performance of mdx-Xist
Dhs with .30% was due to the bad performance of one individual mouse. E. Normalized fore limb grip strength was
significantly (P,0.001) higher in the Xist
Dhs mice compared to the other strains and all the mdx-Xist
Dhs mice were significantly (P,0.001) stronger
than the mdx mice. F. No difference in rotarod running was observed, except for the mdx-Xist
Dhs mice with 15–30% dystrophin, which performed
significantly (P,0.001) better than all other groups.
doi:10.1371/journal.pone.0031937.g002
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mdx suggesting that these dystrophin levels were not enough to
decrease CK levels (Figure 2B).
In the four limb hanging wire test, mdx mice performed
significantly (P,0.001) worse compared to all the other groups
(Figure 2C). Xist
Dhs mice were able to hang for the maximum
period of time for the entire testing period of 12 weeks, whereas all
mdx-Xist
Dhs mice performed nearly as well as Xist
Dhs mice. Also in
the two limb hanging wire test, Xist
Dhs and mdx-Xist
Dhs mice
significantly (P,0.001) outperformed mdx mice and were able to
hang for the maximum allowed time. Performance of mdx-Xist
Dhs
mice with .30% dystrophin dropped from an age of 9 weeks
compared to the other mdx-Xist
Dhs mice, but this was due to the
poor performance of a single mouse. Generally, the decreased
performance was more pronounced in mdx mice (Figure 2D). The
normalized fore limb grip strength measured for Xist
Dhs mice (7.9)
was significantly (P,0.001) higher than that of mdx and mdx-Xist
Dhs
mice (Figure 2E). Strength was improved towards wild type levels
in all mdx-Xist
Dhs mice (6.5) and significantly (P,0.001) lower in
mdx mice (5.9). Rotarod performance was significantly (P,0.001)
better in the mdx-Xist
Dhs mice with 15–30% dystrophin compared
to all the other groups (Figure 2F). Unfortunately, we observed a
high inter group variation, which makes drawing conclusions
difficult for this test. Based on these analyses, even the lowest levels
of dystrophin analyzed (between 3 and 14%), appear sufficient to
improve hanging times and grip strength.
Dystrophin dependent improvement of histopathology
and restoration of gene expression
After sacrificing the animals, the quadriceps, heart and
diaphragm were dissected and cryosections were made. To
determine fiber size and the percentage of centralized nuclei, the
quadriceps of all mice was stained with laminin and DAPI. Five
pictures were randomly captured of the middle section of the
muscle and analysed with Mayachitra Imago (Figure 3A and B).
Regenerating fibers (,1000 mm
2) and hypertrophic fibers
(.6000 mm
2) were predominantly found in the mdx mice (50%
and 4.8%, respectively), whereas smaller proportions were
observed for the Xist
Dhs mice (20% and 0.9%, respectively) and
a dystrophin level dependent normalization towards the wild type
fiber size distribution was observed for mdx-Xist
Dhs mice. The
percentage of centralized nucleated fibers was significantly higher
(P,0.01) in mdx (51%) compared to Xist
Dhs mice (2%). More than
15% of dystrophin was sufficient to significantly (P,0.01) reduce
the amount of centralized nuclei by 40%, whereas dystrophin
levels above 30% caused a reduction of around 60%.
To determine the percentage of fibrotic/necrotic fibers, sections
of the quadriceps, diaphragm and heart were stained with
haematoxylin & eosin. For all muscles quantified, except heart,
the percentage of fibrosis was significantly higher (P,0.001) in mdx
mice compared to Xist
Dhs mice. In the quadriceps of mdx-Xist
Dhs
mice of the different groups no significant differences was
observed, although there appears to be a dystrophin-dependent
trend towards lower levels of fibrosis in the mice with moderate
levels of dystrophin (Figure 3C). The diaphragm was the most
severely affected muscle examined, with fibrotic/necrotic tissue
percentages of 20% in both mdx and mdx-Xist
Dhs mice with ,15%
dystrophin compared to 8% in Xist
Dhs mice. Again, there was a
dystrophin-level dependent pattern of reduced fibrotic tissue which
reached significance (P,0.05) in mice with .30% dystrophin
(Figure 3D). Fibrosis/necrosis levels in heart were below 5% in all
mice, which is expected, as fibrosis in heart generally is observed in
older mice (data not shown) [35].
To determine whether low levels of dystrophin were able to
normalize the expression of genes known to be involved in
inflammation, fibrosis, regeneration and heart function RT-qPCR
was performed on mRNA of the quadriceps, diaphragm and heart
of all mice [36]. The expression of most genes was significantly
(P,0.01) elevated in mdx mice compared to Xist
Dhs mice in the
three muscles, and most often normalized in a dystrophin level
dependent manner in the mdx-Xist
Dhs mice (Figure 4). Notably, in
the diaphragm, mRNA levels of the biomarkers for muscle
regeneration (Tnnt2, Bgn) decreased in mice with ,15%
dystrophin, while biomarkers for inflammation (Lgals3, Cd68) only
decreased in mice with .30% dystrophin. Biomarkers for fibrosis
(Timp-1, Nox2) decreased in mice with ,15% and .15%
dystrophin, respectively. No difference in expression of heart
function genes was observed, except for Nppa, which is due to the
young age of the mice.
Dystrophin level dependent protection against exercise
induced muscle damage
To determine the protective effect of low dystrophin levels on
muscle integrity during chronic exercise, mice were forced to run
three times a week on a horizontal treadmill. This was directly
followed by a functional test to assess the influence of muscle
fatigue on performance. We tested seven mdx-Xist
Dhs mice which
had an average dystrophin level of 21% (2%–45% median 25.8),
six mdx and five C57BL/10ScSnJ females (the wild type sub-strain
from which the mdx mouse was derived).
CK levels were assessed on Mondays before exercise (Figure 5B)
and on Fridays directly after exercise (Figure 5C). For mdx and
mdx-Xist
Dhs mice CK levels increased significantly (P,0.01) upon
exercise (4150 U/L before versus 11170 U/L after for mdx and
2070 U/L before versus 8850 U/L after for mdx-Xist
Dhs), whereas
this was not observed for the wild type mice (250 U/L before
versus 291 U/L after) (Figure 5A). CK levels of the mdx-Xist
Dhs
mice were significantly (P,0.05) lower compared to mdx, both
before and after exercise. Wild type mice had significantly
(P,0.01) lower CK levels than those of mdx and mdx-Xist
Dhs mice.
Mdx-Xist
Dhs mice gained significantly (P,0.01) less weight over
time than mdx mice, as they had a higher body weight at the start,
but a similar body weight at the end of the test regime (data not
shown). Wild type mice were significantly (P,0.01) less heavy than
mdx mice, but did not significantly differ in weight from the mdx-
Xist
Dhs mice.
At an age of 8 and 14 weeks, serum levels of matrix
metalloproteinase-9 (MMP-9), tissue inhibitors of matrix metallo-
proteinase-1 (TIMP-1) and osteopontin (OPN) were assessed.
These markers have been identified as potential biomarkers to
monitor disease progression in DMD patients [37]. For MMP-9, 8
week old mdx mice had significantly (P,0.05) higher levels when
compared to wild type and mdx-Xist
Dhs mice (Figure 5D). No
significant difference was observed between mdx-Xist
Dhs and wild
type mice. TIMP-1 levels were significantly (P,0.05) elevated in
both mdx and mdx-Xist
Dhs mice compared to wild type mice at the
age of 8 and 14 weeks (Figure 5E). Interestingly, a significant
(P,0.05) difference was also observed between mdx and mdx-
Xist
Dhs mice aged 8 weeks. OPN levels were significantly (P,0.05)
elevated in mdx compared to both wild type and mdx-Xist
Dhs at 8
weeks. This difference was not observed at 14 weeks of age
(Figure 5F).
The chronic treadmill exercise protocol was completed by all
mice without any problems. However, we later found that fibrosis
was much worse in these exercised mice and that the low
dystrophin levels were not enough to prevent worsening of the
muscle’s condition (see below). Directly after treadmill exercise,
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strength or rotarod (Figure 6). For the two limb hanging wire test,
the hanging time of mdx mice decreased over time, and was
significantly (P,0.001) lower than those of the mdx-Xist
Dhs and
wild type mice. The hanging time of the mdx-Xist
Dhs and wild type
mice did not differ significantly. Performance of the grip strength
was consistently lower for the mdx mice (5.8) than for the other
groups (mdx-Xist
Dhs 6.3 and wild type 6.4). Wild type mice
performed well at the start of the functional test regime, but their
strength slightly decreased over time. Grip strength of mdx and
mdx-Xist
Dhs mice followed the same curve, and mdx-Xist
Dhs mice
performed significantly (P,0.001) better than mdx mice. Rotarod
running time was significantly (P,0.001) higher in the wild type
mice with an average running time of 430 seconds, which was
generally 130 seconds longer than that of both dystrophic mouse
strains. The performance of mdx and mdx-Xist
Dhs mice did not
significantly differ for this test.
Low dystrophin levels did not fully prevent exercise
induced pathology
The effect of the chronic exercise regime on histopathology was
assessed by measuring the percentage of fibrotic/necrotic tissue for
the quadriceps. On average, 18% of the quadriceps of the mdx
mice consisted of fibrotic/necrotic tissue, compared to less than
5% for wild type mice. Mdx-Xist
Dhs mice had slightly more healthy
tissue than mdx mice (Figure 7A). When compared to fibrosis
observed in mice which underwent the functional test regime
without treadmill running, histopathology was much worse. At the
end of the chronic exercise regime, Evans blue dye was injected
intravenously and the percentage of Evans blue dye positive fibers
was manually counted for the quadriceps of all mice. Hardly any
Evans blue dye positive fibers were detected in wild type muscle
(0.41%), while both in mdx and mdx-Xist
Dhs mice 11.11% and
9.23% of positive fibers were found. This suggests that while low
dystrophin levels are sufficient to improve muscle function and
muscle fiber integrity in the absence of chronic exercise, they
apparently are not sufficient to protect against fiber damage
induced by the chronic treadmill exercise regime.
The expression of some fibrosis, inflammation and regeneration
biomarkers was assessed for the quadriceps. For most genes, mdx
and mdx-Xist
Dhs mice had significantly (P,0.05) increased
expression when compared to wild type levels. However, between
mdx and mdx-Xist
Dhs mice no difference in expression was observed
indicating that the dystrophin levels in these mice were not
Figure 3. Muscle fiber size, degree of central nucleation and percentage of fibrotic/necrotic tissue. A. Regenerating and hypertrophic
fibers were mainly observed in the mdx mice. A dystrophin level depend trend towards wild type distribution was observed for mdx-Xist
Dhs mice
where ,15% dystrophin already resulted in improvement. B. Dystrophin levels between 15–30% and .30% resulted in a reduction of the percentage
of centralized nuclei of 40% and 60% respectively. C. The quadriceps of all mice was significantly more severely affected compared to Xist
Dhs mice. D.
The diaphragm was the most severely affected muscle with on average 20% fibrotic/necrotic tissue in mdx mice. All mice were significantly more
severely affected compared to Xist
Dhs mice. Mdx-Xist
Dhs mice with .30% dystrophin had less fibrotic/necrotic tissue than mdx and mdx-Xist
Dhs mice
with ,15% dystrophin, but this difference was only significant between both mdx-Xist
Dhs groups. # indicates a significant difference of that bar with
all the other groups. Single asterisks indicate a P,0.05 and double asterisks indicate a P,0.01.
doi:10.1371/journal.pone.0031937.g003
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31937Figure 4. Expression of several genes involved in disease pathology. A and B. For most biomarkers a clear dystrophin level dependent
restoration of gene expression levels was observed in the mdx-Xist
Dhs mice, where intermediate dystrophin levels resulted in low expression of genes
involved in disease pathology. For some genes, dystrophin levels ,15% were enough to reduce gene expression while for other genes .30% was
necessary. C. In the heart, even dystrophin levels of ,15% decreased expression of fibrotic biomarkers like Timp-1. Since the mice were young, no
difference in expression levels in heart function was observed, except for Nppa. Double asterisks indicate a P,0.01.
doi:10.1371/journal.pone.0031937.g004
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(Figure 7B). In addition, we were able to confirm the differences
observed in serum for MMP-9, TIMP-1 and OPN (Spp1) on gene
expression level.
Discussion
With several potential therapeutic compounds being tested in
clinical settings for DMD, there is an increasing need to gain
detailed knowledge about which levels of dystrophin are of
therapeutic value and which and/or how low dystrophin levels
affect the different pathological pathways. This would help the
optimization phase of pre-clinical research on therapeutic
approaches aiming at dystrophin restoration. It will also facilitate
providing patients and parents who are candidates to participate in
clinical trials for these approaches with realistic expectations.
Several attempts to generate mice expressing low dystrophin
levels have been undertaken previously, unfortunately without
success since none of these strains expressed a wide variety of low
dystrophin levels in the most interesting range. With no
accessibility to a good model, current knowledge and rough
estimations are based on human female DMD carriers, heterozy-
gous mdx mice, generated transgenic mice expressing lower levels
of full-length or truncated dystrophin of murine or human origin
and antisense oligonucleotide (AON) treated mdx mice.
In this paper, we describe the easy to generate mdx-Xist
Dhs
mouse model, which facilitates assessment of the effects of different
dystrophin levels on muscle performance and integrity. Mice with
very low (,15%), low (15–30%) and moderate dystrophin (.30%)
levels showed a dystrophin level dependent reduction of the
homolog utrophin. All mdx-Xist
Dhs mice had a normalized body
weight and outperformed mdx mice in both hanging wire tests and
in the grip strength test, indicating that even low dystrophin levels
(,15%) can bring about improved performance in this mouse
model. The improved functional performance observed is in
concordance with that previously described in mdx
3cv mice and
AON treated mice expressing low levels of dystrophin [29,38].
Although, ,5% of dystrophin in the mdx
3cv mice resulted in
increased specific tetanic force and partly resistance to eccentric
contractions in young, but not in old mice, histopathology was not
different from dystrophin negative mdx
4cv mice. This again is in line
with our observation in mdx-Xist
Dhs mice expressing ,15%
dystrophin, were we also found no histopathological improve-
ments, while we did find improvements on motor function.
Dystrophin levels .30% reduced CK levels significantly while for
lower percentages only a non-significant trend was found. Also for
the expression of pro-inflammatory biomarkers and histopathol-
ogy, a dystrophin level dependent improvement was observed
where for some genes .15% of dystrophin led to improvement
while for other genes .30% dystrophin was needed. In chronically
exercised mice with ,20% dystrophin, normalization towards
wild type levels was observed for three different disease serum
markers (CK, MMP-9 and TIMP-1). This confirms findings that
MMP-9 and TIMP-1 are useful serum biomarkers to monitor
disease pathology in DMD patients’ serum [37]. Even after
treadmill exercise the mdx-Xist
Dhs mice performed significantly
better than the mdx mice for the two limb hanging wire test and
grip strength. However, the levels of fibrosis and Evans blue dye
uptake were similar for mdx-Xist
Dhs mice and mdx mice, indicating
that ,20% of dystrophin is not sufficient to protect against forced
exercise induced damage. Thus, while even dystrophin levels
below 15% can improve pathology and performance, levels of
.20% are needed to fully protect muscle fibers from exercise-
induced damage.
The fact that most of our observations concur with those of
other studies conducted in transgenic mice and AON treated mice
Figure 5. Serum and plasma biomarkers assessed before and directly after treadmill running. A. CK levels assessed before and directly
after treadmill running. CK levels collected before exercise were significantly (P,0.01) lower than those collected directly after exercise in mdx-Xist
Dhs
and mdx mice. This exercise induced increase was absent in wild type mice. B. CK levels determined before exercise were significantly (P,0.01)
elevated in mdx and mdx-Xist
Dhs mice compared to wild type, but this was less pronounced for the mdx-Xist
Dhs mice as mdx mice had significantly
(P,0.05) higher CK levels. C. Plasma collected directly after exercise contained extremely high CK levels, in both mdx and mdx-Xist
Dhs mice but not in
wild type mice. D. Serum levels of MMP-9 were elevated in mdx mice compared to Xist
Dhs mice at both 8 and 14 weeks of age, while levels were
normalized in mdx-Xist
Dhs mice. E. TIMP-1 levels were elevated in serum of both mdx and mdx-Xist
Dhs mice. In wild type mice we found an age related
increase of the serum TIMP-1 level. Interestingly, at the age of 8 weeks, levels of mdx-Xist
Dhs mice were significantly lower than those of mdx mice. F.
Mdx mice had significantly elevated OPN levels compared to both wild type and mdx-Xist
Dhs at 8 weeks of age. Single asterisks indicate a P,0.05,
average dystrophin level of mdx-Xist
Dhs mice was 21% (2%–45% median 25.8).
doi:10.1371/journal.pone.0031937.g005
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Dhs mouse as a dystrophic
mouse strain. It should be noted that the mdx-Xist
Dhs mouse
expresses dystrophin in a random manner where nuclei either
express wild type levels of dystrophin or no dystrophin at all. This
is similar to the pattern what is expected for cell therapy, gene
therapy and to what is observed in transverse cross sections after
phosphorodiamidate morpholino oligomer (PMO) administration
[12], but different from that of 29-O-methyl phosphorothioate
(2OMePS) [11] or gentamicin administration [39], which result in
a more evenly low dystrophin expression in nearly all fibers. With
detailed knowledge lacking regarding the migration properties of
AONs and dystrophin over the membrane, it is unknown whether
the mosaic pattern seen in longitudinal cross sections of mdx-Xist
Dhs
mice could be expected upon PMO administration. The effect of
differences in distribution of dystrophin has never been studied in
great detail; i.e. whether 20% of dystrophin in all muscles is better
than 100% dystrophin in 20% of muscle fibers. Previously, Phelps
et al. showed that mice expressing dystrophin 10-fold greater than
wild type levels in a mosaic manner had 34% of centralized nuclei,
while mice expressing similar amounts uniformly only had 7% of
central nuclei. More detailed studies especially in mice expressing
low dystrophin levels are needed and could easily be conducted
using our mouse model and comparing them to 2OMePS or
gentamicin treated mdx mice [25]. Using the mdx-Xist
Dhs mouse as
study object is favored above treated mdx mice since no expensive
treatment is needed to achieve a range of low dystrophin levels.
Notably, we observed variation in pathology for mice with similar
levels of dystrophin. This phenomenon is also anticipated for
patients currently in clinical trials aiming at dystrophin restoration.
Our mouse model will allow extended studies to elucidate this
discrepancy.
In summary, the Gaussian distribution of low dystrophin levels
obtained in the mdx-Xist
Dhs mouse and the ease of generating large
numbers of mice, make it a good mouse model for more detailed
research on the effect of low levels of dystrophin on several aspects
of DMD pathology and effects of future treatment strategies for
dystrophinopathies.
Materials and Methods
Ethics statement
All experiments were approved by and performed following the
guidelines of the Dier Experimenten Commissie (Animal Exper-
imental Commission) of the Leiden University Medical Center
(Permit Numbers: 08096 and 09136). Effort was put in minimizing
the amount of distress caused to the animals as much as possible.
Animal care
All studied mouse strains were bred at the animal facility of the
LUMC where they were housed in individually ventilated cages
with 12-h light-dark cycles. The Xist
Dhs model [32] was a kind gift
from Prof Brockdorff (MRC Clinical Sciences Centre London,
UK, current affiliation Department of Biochemistry, University of
Oxford, UK). Mice were given standard chow and water ad libitum
and were weighed two times a week. Breeding pairs of mdx
(C57BL/10ScSn-mdx/J) males and Xist
Dhs females gave birth to
mdx-Xist
Dhs females (Figure 1A). Genotyping was performed on
DNA obtained from tail tips by PCR analysis to confirm the
mutation in the Dmd and Xist gene (primers and PCR conditions
on request).
Functional test regimes
To test the functional abilities of the different mouse strains over
time, a group of 5 mdx,2 4mdx-Xist
Dhs (0–15% dys n=9, 15–30%
dys n=9 and .30% n=6, as assessed by Western blot of
quadriceps muscles at the end of the study) and 5 Xist
Dhs females
underwent a functional test regime consisting of four different
functional tests starting at four weeks of age, as described
previously [40]. Plasma creatine kinase (CK) levels were
determined once a week at the beginning of the functional test
regime. Mice were sacrificed by cervical dislocation after 12 weeks
of testing and muscles were isolated.
To determine whether functional test performances could be
influenced by chronic treadmill exercise, 6 mdx,7mdx-Xist
Dhs and 5
Figure 6. Functional performance measured directly after
treadmill exercise. A. Longest hanging time with the two limb
hanging test was achieved by wild type and mdx-Xist
Dhs mice which
both performed significantly (P,0.001) better than mdx mice. B. Fore
limb grip strength of mdx-Xist
Dhs mice was significantly (P,0.001)
better than that of mdx mice. C. Wild type mice outperformed mdx and
mdx-Xist
Dhs mice on the rotarod, while no significant difference was
observed between mdx and mdx-Xist
Dhs mice. Average dystrophin level
of mdx-Xist
Dhs mice was 21% (2%–45% median 25.8).
doi:10.1371/journal.pone.0031937.g006
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a horizontal treadmill at 12 m/min, directly followed by either
fore limb grip strength, rotarod running or the two limb hanging
wire test three times a week for 12 weeks. CK levels were
determined two times a week; on Mondays before exercise and on
Fridays directly after the two limb hanging wire test. At the age of
8 and 14 weeks additional blood was collected via the tail to assess
several serum biomarkers (MMP-9, TIMP-1 and OPN) of which
we have determined in parallel research that these correlate with
disease severity [37]. After the 12 week chronic exercise protocol,
mice were forced to run a final time on the horizontal treadmill for
30 minutes at 12 m/min. Evans blue dye (5 mg/ml) was applied
intravenously (5 ml/gram of body weight) 20–30 minutes after this
exercise. Twenty four hours after the injection, mice were
sacrificed by cervical dislocation and muscles were isolated.
Standardized operating procedures from the TREAT-NMD
network were implemented for grip strength, both hanging wire
tests and treadmill running (http://www.treat-nmd.eu/resources/
research-resources/dmd-sops/).
Fore limb grip strength test
Fore limb grip strength was assessed by means of a grip strength
meter (Columbus Instruments, USA). Mice were tested five times,
with three consecutive measurements per trial (15 in total), and a
two minute interval between trials. The three highest measured
values were averaged to calculate the absolute strength, which was
divided by the body weight in grams.
Rotarod
Mice were placed on the Rotarod (Ugo Basile, Italy) that
accelerated from 5 to 45 rotations per minute within 15 seconds.
The test session ended when a mouse ran for 500 seconds without
falling. Mice that fell off before 500 seconds were given a
maximum of two more tries. The longest running time was used
for analysis.
Two limb hanging wire test
Mice were suspended above a metal cloth hanger secured above
a cage and released a few seconds after instinctively grasping the
wire with the fore limbs. Depending on the functional ability of the
mouse, 2–4 limbs and the tail were used during a 10 minute
hanging session. Mice that fell down before the 10 minute time
limit were given two more tries. The longest hanging time was
used for further analysis.
Four limb hanging wire test
The start position of this test was with all limbs. To this end,
mice were placed on a grid, which was then turned upside down
above a cage filled with bedding. The session ended after a
hanging time of 10 minutes was achieved or otherwise after three
sessions. The longest hanging time was used for further analysis.
Blood CK, MMP-9, TIMP-1 and OPN level analysis
For CK determination, blood was collected via a small cut at
the end of the tail in a Minicollect tube (0.8 ml Lithium Heparin
Sep, Greiner bio-one, Austria). Plasma CK levels were determined
with Reflotron CK test strips in the Reflotron plus machine
(Roche diagnostics Ltd, UK) at the day of collection.
To detect MMP-9, TIMP-1 and OPN levels, blood was
collected via the tail and allowed to clot at room temperature
for 10 minutes before spinning (1700 g for 10 minutes at 4uC).
The serum supernatant was carefully aspirated and stored at
280uC, before use. To determine serum biomarker levels in
mouse, the mouse MMP-9 (total) immunoassay kit (catalog
number MMPT90) and mouse TIMP-1 immunoassay kit (catalog
number MTM100) were purchased from R&D systems (Abing-
don, United Kingdom), while the mouse OPN kit (code number
27351) was purchased from IBL (Hamburg, Germany). Experi-
ments were performed as per manufacturer’s protocol.
Histological examinations
For all 16 week-old mice the quadriceps, gastrocnemius, tibialis
anterior, triceps, biceps, diaphragm and heart were dissected and
snap frozen in 2-methylbutane (Sigma Aldrich, the Netherlands)
cooled in liquid nitrogen. Cross-sections of 8 mm were cut on
Superfrost Plus slides (Thermo Fishes Scientific, Menzel-Gla ¨ser,
Germany) with a Shandon cryotome (Thermo Fisher Scientific
Co., USA) along the entire length of the muscle with an interval of
240 mm between the sections. The excess tissue between the
sections was collected in MagNa Lyser Green Beads tubes (Roche
diagnostics Ltd, UK) for total RNA and protein isolation.
Figure 7. Exercise induced histopathology and biomarker gene expression. A. Wild type mice were less severely affected than mdx and
mdx-Xist
Dhs mice. Due to high variation between individual mdx mice, the difference between mdx and wild type mice was not significant. Mdx-Xist
Dhs
mice had slightly less fibrotic tissue than mdx mice. B. No difference in expression of genes involved in disease pathology was found between mdx
and mdx-Xist
Dhs mice. Both mouse strains did differ significantly from wild type mice, of which the expression levels were low. Single and double
asterisks indicate a P,0.05 and P,0.01, respectively. # Indicates a significant difference from all other groups, average dystrophin levels of mdx-
Xist
Dhs mice was 21% (2%–45% median 25.8).
doi:10.1371/journal.pone.0031937.g007
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of the quadriceps were stained with Harris Haematoxylin and
Eosin (H&E) (Sigma Aldrich, the Netherlands) and examined with
a light microscope (Leica DM LB, Leica Microsystems, the
Netherlands) at a 5 times magnification and images were captured
with a Leica DC500 camera and Leica IM50 software (Leica
Microsystems, the Netherlands) from the entire middle section of
the muscle. Analysis was performed in a double-blinded manner,
by two independent researchers on stitched pictures with the color
deconvolution plugin of the ImageJ software (Rasband, W.S.,
ImageJ, U. S. National Institutes of Health, Bethesda, Maryland,
USA, http://rsb.info.nih.gov/ij/, 1997–2008) as described previ-
ously [40]. Quadriceps, tibialis anterior, diaphragm and heart
sections were stained with dystrophin (C-20, dilution 1:50, Santa
Cruz, Germany) and donkey-anti-goat Alexa 488 (dilution 1:1000,
Invitrogen, the Netherlands) and mounted with Vectashield
mounting medium including DAPI (Vector Labs, Germany).
The percentage of dystrophin positive fibers was manually and
independently counted by two persons in a blinded manner for the
quadriceps, stained with dystrophin and laminin (ab11575,
dilution 1:50 Abcam, UK) where donkey-anti-goat Alexa 488
and donkey-anti-rabbit Alexa 594 (dilution 1:1000, Invitrogen, the
Netherlands) were respectively used as a secondary antibody. To
determine the dystrophin expression per nucleus, longitudinal
sections of the quadriceps were cut and stained with dystrophin,
spectrin (dilution 1:200, Thermo Scientific, USA) and DAPI. Co-
localization of dystrophin with nNOS (H-299, dilution 1:50, Santa
Cruz, Germany) and b-dystroglycan (NCL b-DG, dilution 1:50,
Novocastra, UK) was determined in the quadriceps. The donkey-
anti-rabbit Alexa 488 (dilution 1:1000, Invitrogen, the Nether-
lands) and MOM kit (Vector Laboratories, UK) were used as
secondary antibody respectively.
Fiber size and the percentage of centrally nucleated fibers were
determined with Mayachitra Imago 1 (http://www.mayachitra.
com/imago/) on five randomly captured images of the quadriceps
stained with laminin and DAPI (van Putten et al. manuscript in
preparation). Fibers were segmented based on intensity differences
between the membrane and the cytoplasm. The cross sectional
area of each segmented fiber was computed by the software.
Centrally nucleated fibers were identified based on the maximum
intensity of the cytoplasm which is higher in fibers with a
centralized nucleus than without. The percentage of Evans blue
dye positive fibers was manually counted in a blinded manner for
the quadriceps of all mice which were subjected to the chronic
treadmill exercise. All fluorescent stained sections were examined
with a fluorescent microscope (Leica DM RA2) at a 16 times
magnification and six images were randomly captured with a
Leica DC350FX snapshot camera.
Western blot analysis
Muscles were homogenized in treatment buffer (100 mM Tris-
HCl pH 6.8 and 25% SDS) using MagNa Lyser green beads tubes
in the MagNa Lyser (Roche Diagnostics, the Netherlands). Protein
concentration was determined using the BCA protein assay kit
(Thermoscientific, USA), according to the manufacturer’s instruc-
tions. Subsequently, the homogenate was complemented to
contain 75 mM Tris-HCl pH 6.8, 15% SDS, 5% b-mercaptoeth-
anol, 20% glycerol and 0.001% bromophenol blue. Samples were
boiled for 5 minutes and 50 mg was loaded on a hand-made 4–7%
gradient polyacrylamide gel and run overnight at 4uC. The gel was
blotted to nitrocellulose BA83 (Whatman, Schleicher & Schuell,
Germany) for 6 hours at 4uC. The blot was blocked with 5% non-
fat dried milk (Campina Melkunie, the Netherlands) in Tris
Buffered Saline (TBS) plus 0.05% Tween20 followed by an
overnight incubation with NCL-DYS1 (dilution 1:125, Novacas-
tra, UK) or MANCHO3 (dilution 1:50,Tebu-bio, the Netherlands)
in TBS plus 0.05% Tween20 to detect dystrophin and utrophin
respectively. Myosin (MF20 dilution 1:20000, Developmental
Studies Hybridoma Bank, University of Iowa, Iowa City) was used
as a loading control. The fluorescent IRDye 800CW goat anti-
mouse IgG (dilution 1:5000 for dystrophin and utrophin, dilution
1:10000 for myosin, Li-Cor, USA) was used as a secondary
antibody. Blots were visualized and quantified with the Odyssey
system and software (Li-Cor, USA) as described previously [41].
For each sample, 2–9 technical replicates were performed. A
standard deviation of 15% was allowed between the replicates.
RT-qPCR analysis
Total RNA was isolated with RNA-Bee (Tel-Test, Bio-Connect,
the Netherlands) and purified with the NucleoSpin RNA II kit
including a DNAse digestion (Bioke, the Netherlands) according to
the manufacturer’s instructions. The RNA concentration was
measured on a Nanodrop (Nanodrop Technologies, USA) and
integrity was checked with a total RNA nano chip assay on a
labchip assay (Agilent, the Netherlands). cDNA was synthesised
with random hexamer primers and gene expression levels were
determined by Sybr Green based Real Time qPCR (95uC 10 sec,
60uC 30 sec, 72uC 20 sec. 45 cycles followed by melting curve
determination) on the Roche Lightcycler 480 (Roche diagnostics
Ltd, UK). Expression of genes involved in inflammation (Lgals3,
Cd68), fibrosis (Tnnt2, Itgb2, Timp-1, Nox2, Lox, Nox4, Mmp9, Spp1)
regeneration (Myog, Bgn, eMHC, Ctsk, Thymosinb), heart function
(Nppa, Serca2a, Cdnk1a) and exercise (Glut4, Pgc1a) were analysed.
Gapdh was used as a reference gene, since the expression of this
gene did not differ between different muscles or over time. Primer
efficiencies were determined with LinREgPCR version 11.1 [42].
The Cp values were obtained with the second derivative maximum
method and analysed.
Statistics
Statistical analyses were performed with statistical software in R
(version R2.11.1). Mdx-Xist
Dhs mice were divided in three groups
by k-means clustering, based on the median level of dystrophin
quantified by Western blot data (n=2–9). Figures 2, 5 and 6
summarize the data, i.e. showing the mean and standard deviation
per genotype and age. To overcome applying separate tests for
each age between genotypes, which suffers from multiple testing
and ignores the age trend, we applied an analysis of covariance
(ANCOVA) to the data. ANCOVA was applied to temporal
functional performance, body weight and CK level data with age
as continuous and genotype as a categorical variable. In choosing
the appropriate model we applied the principle of parsimony.
Given the application of tests for several different variables, we
considered P,0.01 as significant.
The two-tailed homoscedastic Student’s t-test was conducted for
comparison of the single time point histological, serum biomarker
and gene expression data. P,0.05 was considered significant for
all tests, while P,0.01 was used for the gene expression data to
correct for multiple testing.
Supporting Information
Figure S1 Dystrophin expression in mdx-Xist
Dhs mice.
A. Example of a Western blot of some skeletal muscles and heart.
In order to determine the expression levels of the different muscles,
a concentration curve was made of wild type samples from the
corresponding muscle. Myosin was used as a loading control. B.
Relative dystrophin levels of skeletal muscles compared to these of
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PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31937the quadriceps. Dystrophin levels of six mdx-Xist
Dhs mice, with
dystrophin levels of ,15%, 15–30% and .30%, were assessed for
skeletal muscles and heart by Western blot. Levels are expressed
relative to the quadriceps. Those of gastrocnemius and triceps
were similar to quadriceps levels, while those of the tibialis anterior
and the biceps were slightly higher. Low levels were observed for
the diaphragm and heart. qua: quadriceps, gas: gastrocnemius, ta:
tibialis anterior, tri: triceps, bi: biceps, dia: diaphragm, ha: heart.
C. Small groups of dystrophin positive fibers were randomly
distributed over the muscles. Representative pictures of mdx-Xist
Dhs
mice with 8 and 23% dystrophin.
(TIF)
Figure S2 Dystrophin co-localisation with b-dystrogly-
can and nNOS in mdx-Xist
Dhs mice. A. Dystrophin co-
localises with b-dystroglycan (top) and nNOS (bottom). B. For
mdx-Xist
Dhs mice dystrophin levels previously determined on
several Western blots (representative blot shown in Figure 1B)
were compared to utrophin levels. The relative level of utrophin
nicely correlated to that of dystrophin. Mice with intermediate
dystrophin levels had decreased utrophin levels (lane 2 and 6)
while mice with low dystrophin levels had higher utrophin levels
(lane 1, 3–5). Mdx/utrn mice expressing utrophin on zero, one or
two alleles were taken along as controls. Myosin was used as a
loading control.
(TIF)
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